Find a Provider

Ravi K. Amaravadi, MD

Ravi K. Amaravadi, MD Physician

Associate Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Amaravadi is a Penn Medicine employed physician.

Clinical Specialties

Specialties:

  • Medicine
    • Medical Oncology

Programs & Services:

  • Cancer
    • Bladder Cancer
    • Early Phase Clinical Trials - Developmental Therapeutics
    • Kidney Cancer
    • Merkel Cell Carcinoma
    • Penile Cancer
    • Prostate Cancer
    • Skin Cancer
    • Testicular Cancer
    • Urethral Cancer

Board Certification:

  • Medical Oncology, 2006

Conditions & Treatments:

  • Bladder Cancer
  • Cancer Clinical Trials
  • Kidney Cancer
  • melanoma
  • Melanoma
  • Non-Melanoma Skin Cancer
  • Penile Cancer
  • phase 1 clinical trials
  • Prostate Cancer
  • Skin Cancer
  • Testicular Cancer
  • Urethral Cancer

Clinical Interests

Phase I and Phase II Clinical Trials
Melanoma

Practice Locations and Appointments

  • Genito-urinary Oncology

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

  • Melanoma and Pigmented Lesions

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Johns Hopkins University School of Medicine
Residency: Brigham and Women's Hospital
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Association for Cancer Research, National American Association for the Advancement of Science, National American Society of Clinical Oncology, National Austrian Science Fund (FWF),, International Beyond Batten Disease Foundation, International Health Research Ireland, International Melanoma Research Foundation Breakthrough Consortium, National Melanoma Research Foundation, National NCI -J special emphasis panel study section for K awards, National NIH Loan repayment program, National Presage Biosciences, National Sprint Biosciences, International Wistar Institute, Cancer Center, Tumor Microenvironment and Metastases Program, Local

Affiliation

Dr. Amaravadi is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Research Interests:

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Selected Publications:

Twyman-Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, Xu B, Dada H, Odiorizzi P, Herati R, Mansfield K, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma D, Xu X, Feldman M, Gangadhar T, Hahn S, Wherry JE, Vonderheide R, Benci J, Minn A.: Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer Nature : 2015.

Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis GC, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res. : 2015.

Krayya A, Piao S, Xu G, Zhang G, Gimotty PG, Xu X, Amaravadi RK**, Speicher DW**. **Co-senior authors.: Identification of secreted proteins that reflect autophagy dynamics with tumor cells Autophagy 11 (1): 60-74,2015.

Hubbard-Lucey V, Shono Y,Maurer K,West ML,Singer NV, Ziegler CG, Lezcano, C, Motta AC,Schmid K,Levi SM,Murphy GF,Liu C,Winkler JD,Amaravadi JK,Rogler G,Dickinson AM,Holler E,van den Brink M,Cadwell K: Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells Immunity : http://dx.doi.org/10.1016/j.immuni.2014.09.011,2014.

Choe, C, Mcarthur GA, Yang M, Caro I, Kempen JH, Amaravadi RK: Ocular Toxicity in BRAF Mutant Melanoma Patients Treated With Vemurafenib Am J. Ophthalmology 158 (4): 831-37,2014.

Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH: Phase I and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in dogs with spontaneously occurring lymphoma. Autophagy 10 (8): 2014.

Myrna R. Rosenfeld, Jeffrey G. Supko, Stuart A. Grossman, Steven Brem, Tom Mikkelson, Daniel Wang, Claire Chang, Janice Hu, Quentin McAfee, Andrea Troxel, Shengfu Piao, Daniel Hetjian, Kay See Tan, Laura Pontiggia, Peter J. O’Dwyer, Lisa E. Davis, Ravi K.Amaravadi: A Phase I/II Trial of Hydroxychloroquine in Conjunction with Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme Autophagy 10 (8): 2014.

Rangwala R, Chang YC, Hu J, Algazy K, Evans T, Fecher L, Schuchter L, Torigian DA, Panosian J, Troxel A, Tan KS, Heitjan DF, Demichele A, Vaughn D, Redlinger M, Alavi A, Kaiser J, Pontiggia L, Davis LE, O'Dwyer PJ, Amaravadi RK.: Combined mTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma Autophagy (2012 IF 12) 10 (8): 2014.

Rangwala R, Leone R, Chang YC, Fecher L, Schuchter L, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel A, Evans T, Demichele A, Nathanson KL, O'Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK.: Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma Autophagy 10 (8): 2014.

Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi R, Davis LE, Mita A, Curiel TJ, Espitia CM, Nawrocki ST, Giles FJ, Carew JS.: Combined Inhibition of Autophagy and HDAC inhibition: A Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Analysis of Hydroxychloroquine in Combination with the HDAC Inhibitor Vorinostat in Patients with Advanced Solid Tumors Autophagy (2012 IF 12) 10 (8): 2014.

Academic Contact Info

Hematology-Oncology Division
University of Pennsylvania
16 Penn Tower
3400 Spruce St.

Philadelphia, PA 19104
Phone: (215) 662-7402
Fax: (215) 349-8550
Patient appointments: 800-789-PENN (7366)

Related Links